CFLAR and cancer: It is well documented that c-FLIP isoforms induce resistance to death receptor ligands such as TRAIL, chemotherapeutic agents, and various cell death mechanisms in malignant cells, and is a rational target for modulating therapy-resistant human malignances Transitory pharmacological inhibition of c-FLIP is adequate to sensitize cancer cells to chemotherapeutics.